

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.

In this photo illustration, the Moderna logo is seen displayed on a smartphone screen with the logo of the Covax Facility in the background. (Photo Illustration: Rafael Henrique/SOPA Images/LightRocket via Getty Images)
Oxfam America filed a complaint Tuesday with the Securities and Exchange Commission that accuses vaccine maker Moderna of making "deceptive and ambiguous statements" that "were designed to hide damaging information from investors," in violation of disclosure laws.
Those alleged "misleading statements" center on Moderna's ongoing dispute with the U.S. government regarding intellectual property rights to the mRNA Covid-19 vaccine developed in collaboration with the National Institutes of Health, and the language the company used to convey that fight in reports to shareholders.
"The fact that Moderna relies so heavily upon this disputed product as the exclusive source of its profits, that its vaccine is subject to intense public and governmental scrutiny, and that an average reasonable investor would have found the U.S. government-Moderna dispute a critical element in determining the stock's value all indicate the company failed to disclose a material risk," the whistleblower complaint, seen by Common Dreams, states.
The filing comes amid sustained criticism of Big Pharma's control over life-saving Covid-19 vaccines--including Moderna's--and demands that pharmaceutical companies share their vaccine technology with the world to help counter stark and ongoing global vaccine inequity. That call has only become more urgent in light of the highly transmissible Omicron variant.
The complaint comes just days after Moderna put at least a temporary pause on its fight with the National Institutes of Health (NIH) over patent rights, because the company put a hold on acquiring the patent. As the Washington Post reported:
Moderna had disputed some claims by NIH that federal scientists were responsible for the invention of the company's mRNA coronavirus vaccine, complicating the government's ability to license the patent and share it with vaccine makers around the world. Government scientists worked with Moderna in January 2020 to rapidly develop the spike protein technology that underpins the vaccine.
While Moderna had acknowledged NIH-funded scientists' role in devising the vaccine, some of its patent applications excluded the government's contributions, advocacy group Public Citizen told reporters last month.
"Moderna believes that its scientists invented the specific mRNA sequence at the heart of the patent in question," according to the company's statement. "The company acknowledges that NIH feels equally strongly that its scientists should be listed as co-inventors for their contemporaneous work on the protein sequence."
"Patent holders could seek a cut of the shot's billions of dollars in sales," the Wall Street Journal noted, "though NIH hasn't said whether it is interested in royalties."
Last week's development, according to the filing, doesn't eliminate the threat of litigation with the federal government but simply "kicks the can down the road."
It's also evidence Moderna "is likely aware that this patent dispute is taking a reputational toll and could lead to a costly lawsuit," the filing states.
Moderna did not, however, clearly convey this information in its recent reports to shareholders.
Instead, the company says it "may be subject to legal proceedings" and as such concealed the fact that "the NIH is openly contemplating litigation because of the company's refusal to share inventorship credit" and hid "damaging information from investors."
Diana Kearney, senior legal advisor for legal and shareholder advocacy at Oxfam America, said Moderna must be held accountable.
"Instead of being transparent and using its life-saving technology to help curb the pandemic," Kearney said in a statement, "Moderna is doing the opposite, obfuscating its patent dispute with the U.S. government, ignoring the death and suffering of millions worldwide, and declining to share their technology to help alleviate the stranglehold that Covid-19 has placed on the global economy."
"Few times in history has a single corporation exercised such a massive influence on the world's trajectory, impacting nearly all of humankind's physical, mental, and financial health," she added, calling Moderna "uniquely positioned to speed the end of the pandemic if it is transparent and shares its technology."
"In light of the company's misguided pursuit of short-term profit over transparency for its investors, and the deadly consequences this may have for millions," said Kearney, "Oxfam is calling on the SEC to investigate and help hold the company to account."
This country and this world are at a monumental crossroads. US voters have an opportunity to beat back the forces of fascism and confront the billionaires who are rigging the economy, our media system, and our democracy, making it increasingly impossible for ordinary people to get by. We’re not just talking about the election. We’re talking about what must be done once these fascist elements are vanquished from power. We need a bolder set of solutions than what either major party has so far been willing to offer and a working-class movement ready to fight like hell for it. Trump didn't emerge from nowhere. The conditions that fueled MAGA authoritarianism were created by decades of radical neoliberal economic policies and a corrupt political system dominated by corporate interests. They slashed taxes on the super-rich, promising that the benefits would trickle down. They said giveaways to the corporate titans would make life more affordable for the rest of us. It was all bullshit. And when a bitter, betrayed populace searches for someone to blame, right-wing demagogues have little trouble finding scapegoats. People know when they're being lied to, but you won't hear any of this from the corporate media. Only independent journalism—powered and funded by people who believe in building a better world—can deliver truly trustworthy daily news. If you share our vision, please contribute whatever you can to sustain our work. |
Oxfam America filed a complaint Tuesday with the Securities and Exchange Commission that accuses vaccine maker Moderna of making "deceptive and ambiguous statements" that "were designed to hide damaging information from investors," in violation of disclosure laws.
Those alleged "misleading statements" center on Moderna's ongoing dispute with the U.S. government regarding intellectual property rights to the mRNA Covid-19 vaccine developed in collaboration with the National Institutes of Health, and the language the company used to convey that fight in reports to shareholders.
"The fact that Moderna relies so heavily upon this disputed product as the exclusive source of its profits, that its vaccine is subject to intense public and governmental scrutiny, and that an average reasonable investor would have found the U.S. government-Moderna dispute a critical element in determining the stock's value all indicate the company failed to disclose a material risk," the whistleblower complaint, seen by Common Dreams, states.
The filing comes amid sustained criticism of Big Pharma's control over life-saving Covid-19 vaccines--including Moderna's--and demands that pharmaceutical companies share their vaccine technology with the world to help counter stark and ongoing global vaccine inequity. That call has only become more urgent in light of the highly transmissible Omicron variant.
The complaint comes just days after Moderna put at least a temporary pause on its fight with the National Institutes of Health (NIH) over patent rights, because the company put a hold on acquiring the patent. As the Washington Post reported:
Moderna had disputed some claims by NIH that federal scientists were responsible for the invention of the company's mRNA coronavirus vaccine, complicating the government's ability to license the patent and share it with vaccine makers around the world. Government scientists worked with Moderna in January 2020 to rapidly develop the spike protein technology that underpins the vaccine.
While Moderna had acknowledged NIH-funded scientists' role in devising the vaccine, some of its patent applications excluded the government's contributions, advocacy group Public Citizen told reporters last month.
"Moderna believes that its scientists invented the specific mRNA sequence at the heart of the patent in question," according to the company's statement. "The company acknowledges that NIH feels equally strongly that its scientists should be listed as co-inventors for their contemporaneous work on the protein sequence."
"Patent holders could seek a cut of the shot's billions of dollars in sales," the Wall Street Journal noted, "though NIH hasn't said whether it is interested in royalties."
Last week's development, according to the filing, doesn't eliminate the threat of litigation with the federal government but simply "kicks the can down the road."
It's also evidence Moderna "is likely aware that this patent dispute is taking a reputational toll and could lead to a costly lawsuit," the filing states.
Moderna did not, however, clearly convey this information in its recent reports to shareholders.
Instead, the company says it "may be subject to legal proceedings" and as such concealed the fact that "the NIH is openly contemplating litigation because of the company's refusal to share inventorship credit" and hid "damaging information from investors."
Diana Kearney, senior legal advisor for legal and shareholder advocacy at Oxfam America, said Moderna must be held accountable.
"Instead of being transparent and using its life-saving technology to help curb the pandemic," Kearney said in a statement, "Moderna is doing the opposite, obfuscating its patent dispute with the U.S. government, ignoring the death and suffering of millions worldwide, and declining to share their technology to help alleviate the stranglehold that Covid-19 has placed on the global economy."
"Few times in history has a single corporation exercised such a massive influence on the world's trajectory, impacting nearly all of humankind's physical, mental, and financial health," she added, calling Moderna "uniquely positioned to speed the end of the pandemic if it is transparent and shares its technology."
"In light of the company's misguided pursuit of short-term profit over transparency for its investors, and the deadly consequences this may have for millions," said Kearney, "Oxfam is calling on the SEC to investigate and help hold the company to account."
Oxfam America filed a complaint Tuesday with the Securities and Exchange Commission that accuses vaccine maker Moderna of making "deceptive and ambiguous statements" that "were designed to hide damaging information from investors," in violation of disclosure laws.
Those alleged "misleading statements" center on Moderna's ongoing dispute with the U.S. government regarding intellectual property rights to the mRNA Covid-19 vaccine developed in collaboration with the National Institutes of Health, and the language the company used to convey that fight in reports to shareholders.
"The fact that Moderna relies so heavily upon this disputed product as the exclusive source of its profits, that its vaccine is subject to intense public and governmental scrutiny, and that an average reasonable investor would have found the U.S. government-Moderna dispute a critical element in determining the stock's value all indicate the company failed to disclose a material risk," the whistleblower complaint, seen by Common Dreams, states.
The filing comes amid sustained criticism of Big Pharma's control over life-saving Covid-19 vaccines--including Moderna's--and demands that pharmaceutical companies share their vaccine technology with the world to help counter stark and ongoing global vaccine inequity. That call has only become more urgent in light of the highly transmissible Omicron variant.
The complaint comes just days after Moderna put at least a temporary pause on its fight with the National Institutes of Health (NIH) over patent rights, because the company put a hold on acquiring the patent. As the Washington Post reported:
Moderna had disputed some claims by NIH that federal scientists were responsible for the invention of the company's mRNA coronavirus vaccine, complicating the government's ability to license the patent and share it with vaccine makers around the world. Government scientists worked with Moderna in January 2020 to rapidly develop the spike protein technology that underpins the vaccine.
While Moderna had acknowledged NIH-funded scientists' role in devising the vaccine, some of its patent applications excluded the government's contributions, advocacy group Public Citizen told reporters last month.
"Moderna believes that its scientists invented the specific mRNA sequence at the heart of the patent in question," according to the company's statement. "The company acknowledges that NIH feels equally strongly that its scientists should be listed as co-inventors for their contemporaneous work on the protein sequence."
"Patent holders could seek a cut of the shot's billions of dollars in sales," the Wall Street Journal noted, "though NIH hasn't said whether it is interested in royalties."
Last week's development, according to the filing, doesn't eliminate the threat of litigation with the federal government but simply "kicks the can down the road."
It's also evidence Moderna "is likely aware that this patent dispute is taking a reputational toll and could lead to a costly lawsuit," the filing states.
Moderna did not, however, clearly convey this information in its recent reports to shareholders.
Instead, the company says it "may be subject to legal proceedings" and as such concealed the fact that "the NIH is openly contemplating litigation because of the company's refusal to share inventorship credit" and hid "damaging information from investors."
Diana Kearney, senior legal advisor for legal and shareholder advocacy at Oxfam America, said Moderna must be held accountable.
"Instead of being transparent and using its life-saving technology to help curb the pandemic," Kearney said in a statement, "Moderna is doing the opposite, obfuscating its patent dispute with the U.S. government, ignoring the death and suffering of millions worldwide, and declining to share their technology to help alleviate the stranglehold that Covid-19 has placed on the global economy."
"Few times in history has a single corporation exercised such a massive influence on the world's trajectory, impacting nearly all of humankind's physical, mental, and financial health," she added, calling Moderna "uniquely positioned to speed the end of the pandemic if it is transparent and shares its technology."
"In light of the company's misguided pursuit of short-term profit over transparency for its investors, and the deadly consequences this may have for millions," said Kearney, "Oxfam is calling on the SEC to investigate and help hold the company to account."